Cardinal aligns manufacturing units
Cardinal Health names David Schlotterbeck to the new position of chief executive officer of pharmaceutical and medical products with oversight of the company's manufacturing businesses. Previously responsible for the Clinical Technologies & Services unit, Schlotterbeck is now also responsible for Cardinal's Pharmaceutical Technologies & Services and Medical Products Manufacturing segments. "The new structure will foster a uniform approach to lean manufacturing and Six Sigma initiatives, and common processes for innovation, research and development, and sourcing," Cardinal said. The change is not part of the wholesaler's restructuring initiative, which began in late 2004...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.